Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

Thomas O’Hare, Christopher A. Eide, Michael W. Deininger · Blood · 2007 · 640 citations · Full text

Medicine, Cancer Biology, Oncology +16

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(ϕ)-LMC GROUP)

Franck E. Nicolini, Sélim Corm, Q.H. Le et al. · Leukemia · 2006 · 203 citations

Life Sciences, Genetics, Hematology +15

Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

Susan Branford, Junia V. Melo, Timothy P. Hughes · Blood · 2009 · 200 citations

Medicine, Hematology, Oncology +8

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib

Jamshid S. Khorashad, Mona Anand, David Marin et al. · Leukemia · 2006 · 148 citations

Life Sciences, Genetics, Molecular Biology +10

Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation

Franck E. Nicolini, Michael J. Mauro, Giovanni Martinelli et al. · Blood · 2009 · 137 citations

Medicine, Hematology, Oncology +15